Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Prognosis and Long-Term Monitoring

At a Glance

Epilepsy with auditory features can remain a long-term condition, but seizure freedom is possible and remission rates rise over time in cohort studies. Tracking every aura, taking medication as prescribed, maintaining sleep, and regular specialist follow-up support safety and quality of life.

Long-term management of Epilepsy with Auditory Features (EAF) is less about “curing” the condition and more about finding a stable balance between seizure control and quality of life [1]. While many patients find a medication that works well, the road to long-term terminal remission—defined as being completely seizure-free for at least five consecutive years—can vary significantly from person to person [2].

Long-Term Remission Rates

Data from a large study that followed EAF patients for an average of 11 years provides a modeled picture of what to expect based on that cohort’s outcomes [2]:

  • Initial Years: After 10 years of living with the condition, an estimated 26.6% of patients achieved terminal remission [2].
  • Mid-Term: By 20 years, that number rose to an estimated 35.7% [2].
  • Long-Term: At 30 years from their first symptoms, an estimated 51.6% of patients had achieved at least five years of seizure freedom [2].

It is important to note that even for those who do not reach the “five-year” milestone, many experience significantly fewer and less intense seizures than they did at diagnosis [2]. However, EAF is generally considered a persistent condition; among those who had not reached terminal remission, nearly 63% had experienced a seizure within the previous year [2].

Factors Affecting Your Prognosis

In that study cohort, researchers looked at several “predictive factors” associated with harder-to-control seizures (though these are cohort associations, not a personal forecast):

  • Early Onset: Seizures began at or before the age of 10 [2][3].
  • Nocturnal Seizures: Seizures primarily happening while you are asleep [3].
  • Complex Hallucinations: Hearing structured sounds like voices or music, rather than just “distortions” [2].
  • Abnormal EEG: An initial EEG that showed specific “focal” electrical spikes in the temporal lobe [2].

Living with EAF: Quality of Life and Safety

Because EAF seizures can involve aphasia (losing the ability to understand or use language), they can be particularly disruptive to social life and employment [1][4].

  • Driving: Legal seizure-free driving intervals vary substantially by country and state. You must check your local licensing authority and speak with your clinician before driving. A single breakthrough seizure can reset this clock [4].
  • Practical Safety: Consider taking showers rather than baths, ensure supervision while swimming, and avoid unprotected heights.
  • Stigma and Anxiety: Even when seizures are controlled, many patients report “felt stigma”—a lingering worry or shame about their condition [5]. Managing the fear of a seizure with counseling or mental health support is as important as managing the seizures themselves [5].
  • Sleep Hygiene: Since sleep is a common trigger, maintaining a consistent sleep schedule is a critical part of your “non-medical” treatment [3].

Safety and SUDEP

Sudden Unexpected Death in Epilepsy (SUDEP) is a very rare but clinically important concern in all types of epilepsy [6]. The risk is highest for people who have frequent “grand mal” or tonic-clonic seizures, especially at night [7][8].

  • Genetic Risks: There is emerging evidence looking at whether people with a mutation in the DEPDC5 gene may have a slightly higher risk of SUDEP [9][10], but you should discuss this with an expert rather than relying on the gene result alone.
  • Prevention: The best way to reduce this risk is to take your medication exactly as prescribed to prevent the seizure activity from spreading [11][6]. For those with frequent night seizures, using a monitoring device that alerts a caregiver may act as an optional adjunct, but these devices do not prevent SUDEP and have false alarms [12].

Monitoring Your Progress

Regular follow-ups with a neurologist or an epileptologist are standard [13]. These visits are used to:

  1. Review your seizure diary: Keep track of every aura, no matter how small, as “minor” sounds can signal that your medication dose needs adjustment [14].
  2. Monitor side effects and labs: Check for medication impacts on memory, mood, or language [13], and schedule routine lab monitoring.
  3. Adjust treatment: If you have been seizure-free for many years, you and your doctor may carefully weigh the risks and benefits of reducing your medication [1].

Common questions in this guide

How likely is long-term remission with epilepsy with auditory features?
Terminal remission means being seizure-free for at least five consecutive years. In one long-term study cohort, modeled estimates of terminal remission were 26.6% after 10 years, 35.7% after 20 years, and 51.6% after 30 years, but these group results cannot predict one person’s outcome.
What features may make EAF seizures harder to control?
In one cohort, seizures beginning at age 10 or younger, seizures during sleep, complex auditory experiences such as voices or music, and focal temporal-lobe spikes on an EEG were linked with more difficult seizure control. These are group-level associations, not a personal prediction.
What should I record between epilepsy follow-up visits?
Keep a seizure diary that includes every aura or unusual sound, even if you remain conscious. At follow-up, your neurologist or epileptologist can review these events, medication effects on memory, mood, or language, laboratory monitoring, and whether treatment needs adjustment.
How can I reduce the risk of SUDEP?
Taking antiseizure medicine exactly as prescribed and working with your clinician to prevent seizures, especially tonic-clonic seizures, is the main way to reduce SUDEP risk. A nighttime alert device may notify a caregiver but does not prevent SUDEP and can give false alarms.
When can I drive again after an EAF seizure?
The seizure-free period required for driving varies by country and state, so check your local licensing authority and ask your clinician before driving. A breakthrough seizure may restart the required waiting period.
What can I do to stay safe and protect my quality of life?
Use showers rather than baths, have supervision when swimming, avoid unprotected heights, and keep a regular sleep schedule. Counseling or mental health support can also help with seizure-related anxiety, stigma, and disruption to social or work activities.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Epilepsy with auditory features.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific seizure types (like simple sounds vs. complex hallucinations), what is my statistical likelihood of long-term remission?
  2. 2.If I have focal epileptiform activity on my EEG, how does that change our approach to my long-term monitoring?
  3. 3.Since I have a DEPDC5 mutation, do I have a higher risk of SUDEP, and should I use a nocturnal seizure-monitoring device?
  4. 4.How many months or years of seizure freedom do I need before we can discuss regaining my driver's license?
  5. 5.If my medication is working well, do I still need regular follow-up EEGs or MRIs, or is our monitoring primarily based on my symptoms?

References

References (14)
  1. 1

    Epilepsy With Auditory Features: From Etiology to Treatment.

    Furia A, Licchetta L, Muccioli L, et al.

    Frontiers in neurology 2021; (12()):807939 doi:10.3389/fneur.2021.807939.

    PMID: 35153984
  2. 2

    Epilepsy with auditory features: Long-term outcome and predictors of terminal remission.

    Bisulli F, Menghi V, Vignatelli L, et al.

    Epilepsia 2018; (59(4)):834-843 doi:10.1111/epi.14033.

    PMID: 29464704
  3. 3

    Predictors of drug-resistance in epilepsy with auditory features.

    Zhang L, Zhu X, Peng A, et al.

    Epilepsy research 2020; (164()):106353 doi:10.1016/j.eplepsyres.2020.106353.

    PMID: 32447239
  4. 4

    Evolution of epilepsy comorbidities in seizure free patients: Is no seizure a synonym of no epilepsy?

    Lagarde S, Bartolomei F

    Revue neurologique 2025; (181(5)):456-470 doi:10.1016/j.neurol.2025.04.004.

    PMID: 40246676
  5. 5

    Felt stigma in seizure-free persons with epilepsy: Associated factors and its impact on health-related quality of life.

    Lee SA,

    Epilepsy & behavior : E&B 2021; (122()):108186 doi:10.1016/j.yebeh.2021.108186.

    PMID: 34252827
  6. 6

    Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

    Harden C, Tomson T, Gloss D, et al.

    Epilepsy currents 2017; (17(3)):180-187 doi:10.5698/1535-7511.17.3.180.

    PMID: 28684957
  7. 7

    Clinical risk factors in SUDEP: A nationwide population-based case-control study.

    Sveinsson O, Andersson T, Mattsson P, et al.

    Neurology 2020; (94(4)):e419-e429 doi:10.1212/WNL.0000000000008741.

    PMID: 31831600
  8. 8

    Seizure freedom and reducing the risk of sudden unexpected death in patients with focal epilepsy treated with cenobamate or other antiseizure medications.

    Sperling MR, Rosenfeld WE, Watson J, Klein P

    Epilepsia 2025; (66 Suppl 1()):4-14 doi:10.1111/epi.18307.

    PMID: 40105710
  9. 9

    The landscape of epilepsy-related GATOR1 variants.

    Baldassari S, Picard F, Verbeek NE, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(2)):398-408 doi:10.1038/s41436-018-0060-2.

    PMID: 30093711
  10. 10

    SUDEP risk and autonomic dysfunction in genetic epilepsies.

    Sahly AN, Shevell M, Sadleir LG, Myers KA

    Autonomic neuroscience : basic & clinical 2022; (237()):102907 doi:10.1016/j.autneu.2021.102907.

    PMID: 34773737
  11. 11

    Sudden unexpected death in epilepsy.

    Friedman D

    Current opinion in neurology 2022; (35(2)):181-188 doi:10.1097/WCO.0000000000001034.

    PMID: 35102124
  12. 12

    Risk Factors for Sudden Unexpected Death in Epilepsy (SUDEP) and Their Mitigation.

    Whitney R, Donner EJ

    Current treatment options in neurology 2019; (21(2)):7 doi:10.1007/s11940-019-0547-4.

    PMID: 30758730
  13. 13

    Current challenges in focal epilepsy treatment: An Italian Delphi consensus.

    Di Gennaro G, Lattanzi S, Mecarelli O, et al.

    Epilepsy & behavior : E&B 2024; (155()):109796 doi:10.1016/j.yebeh.2024.109796.

    PMID: 38643659
  14. 14

    Long-Term Adherence to a Subcutaneous Two-Channel EEG System in Patients With Focal Epilepsy.

    Zabler N, Novitskaya Y, Sprünken R, et al.

    Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2026; (43(2)):150-156 doi:10.1097/WNP.0000000000001169.

    PMID: 40391995

This page is for informational purposes only and does not predict your individual EAF prognosis or replace medical advice. Discuss medication changes, driving, SUDEP concerns, and monitoring with your neurologist or epileptologist.